Oppenheimer downgraded Spruce Biosciences (SPRB) to Perform from Outperform without a price target The company announced disappointing topline results from both of its ongoing trials of tildacerfont, the analyst tells investors in a research note. The firm awaits clarity on next steps with Spruce winding down both trials and prioritizing cash conservation as it evaluates strategic alternatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences downgraded to Market Perform from Outperform at JMP
- Spruce Biosciences Inc trading resumes
- Spruce Biosciences Inc trading halted, news pending
- Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint
- Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?